Keyword: New Enterprise Associates
The cash sets Intact up to advance a clinical development program designed to generate data to support FDA approval of the Tack Endovascular System.
The device is designed to enable the remote monitoring of heart failure patients and thereby improve outcomes.
Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.
The series C sets Amplyx up to take its lead broad-spectrum antifungal candidate into phase 2 later this year.
Canaan will continuw the strategy that has delivered it paydays as companies including J&J and Teva have snapped up pieces of its portfolio.
Senseonics is set to raise $41 million to support commercialization of implantable continuous glucose monitoring system Eversense.
Intrinsic Therapeutics raised $49 million for its implant that addresses challenges in spinal surgery to remove a herniated disc.
Advanced Cardiac Therapeutics raised $45 million in equity, which will drive global clinical development for its next-generation ablation catheter.
Deborah Dunsire has achieved the rare feat, on International Women’s Day no less, of becoming CEO of an early-stage biotech after being officially named as XTuit Pharmaceuticals’ leader today.
Relievant Medsystems reeled in $36 million that will propel the clinical development and commercialization prep for its nerve ablation system for chronic back pain.